RxDoctor Payments Data

Elissa Gartenberg, DO

Family Medicine · Scottsdale, AZNPI 1639152291

Payments from drug & device makers

$2,869in general payments, 2019–2025

Across 134 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$707
  • Novo Nordisk$657
  • Lilly USA, LLC$385
  • Lucid Diagnostics Inc.$258
  • Amgen$193
  • Teva Pharmaceuticals USA, Inc.$106
  • plus $562 from 21 others

What the payments were for

  • Travel & lodging$201%
  • Food & beverage$2,84999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,869 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$100,965
Medicare patients
112
Services billed
694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$27,835
MounjaroTirzepatide13$14,951
SynthroidLevothyroxine Sodium12$536
Rosuvastatin Calcium28$398
Losartan Potassium49$334
Gabapentin24$316
Liothyronine Sodium12$291
Fluticasone Propionate19$256
Duloxetine Hcl11$253
Escitalopram Oxalate24$242
Levothyroxine Sodium49$234
Lisinopril21$226
Metformin Hcl ErMetformin Hcl39$169
Metoprolol Succinate17$168
Atorvastatin Calcium26$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$657$27,83518 claims
Lilly USA, LLCMounjaro$385$14,95113 claims
AbbVieSynthroid$707$53612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →